Harper L, Ferreira M A, Howie A J, Savage C O, Richards N T, Michael J, Adu D
Department of Nephrology, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
J Nephrol. 2000 Sep-Oct;13(5):360-6.
Patients with IgA nephropathy and histological vasculitic/crescentic lesions have a poor prognosis. We performed a retrospective study to assess whether treatment with steroids and immunosuppressants would preserve renal function by healing these lesions and thereby prevent progression to glomerular sclerosis and renal failure.
Sixteen patients with IgA nephropathy and a vasculitic/crescentic glomerulonephritis diagnosed by renal histology were treated with a reducing course of prednisolone (initial dose 60 mg/day). Six patients also received cyclophosphamide (2 mg/kg/day) for three months followed by azathioprine (100 mg/day) in five patients. Ten patients received azathioprine (100 mg/day) in addition to prednisolone. The median duration of treatment was 12 months (range 5-30 months). At the end of treatment each patient had a second renal biopsy.
Following treatment there was a significant reduction in the proportion of glomeruli with acute vasculitic lesions from a median of 17.4% (range 4.8-57.5%) to 0 (range 0-15.8%) (p=0.001). There was an increase in the proportion of globally sclerosed glomeruli from a median of 13.4% (range 0-44.4%) to 21.5% (range 0-90%) after treatment but this did not significantly differ from baseline (p=0.24). The proportion of renal cortex with chronic tubular atrophy increased from 2.55% (0.4-57.7%) to 11.3% (0.3-61%) (p=0.09). The median duration of follow-up was 30 months (inter-quartile range 6-30 months). At both 12 and 24 months there was no significant increase in serum creatinine. Four patients, however, developed end-stage renal failure between 24 and 81 months.
In this retrospective study we show that treatment with steroids and immunosuppressants leads to healing of vasculitic lesions and may thus arrest progression of glomerular scarring.
患有IgA肾病且伴有组织学血管炎/新月体病变的患者预后较差。我们进行了一项回顾性研究,以评估使用类固醇和免疫抑制剂进行治疗是否能通过治愈这些病变来保留肾功能,从而防止进展为肾小球硬化和肾衰竭。
16例经肾组织学诊断为IgA肾病合并血管炎/新月体性肾小球肾炎的患者接受了递减疗程的泼尼松龙治疗(初始剂量60mg/天)。6例患者还接受了3个月的环磷酰胺治疗(2mg/kg/天),随后5例患者接受硫唑嘌呤治疗(100mg/天)。10例患者在接受泼尼松龙治疗的基础上还接受了硫唑嘌呤治疗(100mg/天)。治疗的中位持续时间为12个月(范围5 - 30个月)。治疗结束时,每位患者均接受了第二次肾活检。
治疗后,伴有急性血管炎病变的肾小球比例从中位值17.4%(范围4.8 - 57.5%)显著降至0(范围0 - 15.8%)(p = 0.001)。治疗后全球硬化性肾小球的比例从中位值13.4%(范围0 - 44.4%)增至21.5%(范围0 - 90%),但与基线相比无显著差异(p = 0.24)。肾皮质慢性肾小管萎缩的比例从2.55%(0.4 - 57.7%)增至11.3%(0.